REGENERON PHARMACEUTICALS, INC. (REGN) Spending and interest coverage
- R&D / revenue · 12 months: Value 40.40%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 6.35%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 40.40% | Research and development expense / revenue. Period ending 2026-06-30. $6.28B ÷ $15.53B × 100 ≈ 40.40% |
| Stock-based compensation / revenue · 12 months | 6.35% | Share-based compensation / revenue. Period ending 2026-06-30. $986.70M ÷ $15.53B × 100 ≈ 6.35% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 6.28B USD | Research and Development Expense |
| Revenue | 15.53B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 986.70M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 3.84B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.28B | $15.53B | $986.70M | $3.84B | (m) | 40.40% | 6.35% | (m) | (m) |
| 2026-03-31 | $6.07B | $14.92B | $995.40M | $3.63B | (m) | 40.66% | 6.67% | (m) | (m) |
| 2025-12-31 | $5.85B | $14.34B | $993.70M | $3.58B | (m) | 40.79% | 6.93% | (m) | (m) |
| 2025-09-30 | $5.64B | $14.25B | $1.05B | $3.69B | (m) | 39.56% | 7.36% | (m) | (m) |
| 2025-06-30 | $5.43B | $14.21B | $1.04B | $3.84B | (m) | 38.22% | 7.29% | (m) | (m) |
| 2025-03-31 | $5.21B | $14.09B | $1.01B | $3.83B | (m) | 36.99% | 7.16% | (m) | (m) |
| 2024-12-31 | $5.13B | $14.20B | $982.80M | $3.99B | (m) | 36.14% | 6.92% | (m) | (m) |
| 2024-09-30 | $4.90B | $13.85B | $918.80M | $3.97B | (m) | 35.37% | 6.64% | (m) | (m) |
| 2024-06-30 | $4.70B | $13.49B | $897.60M | $3.90B | (m) | 34.85% | 6.65% | (m) | (m) |
| 2024-03-31 | $4.59B | $13.10B | $876.40M | $3.85B | $71.10M | 35.01% | 6.69% | 54.17× | Reported |
| 2023-12-31 | $4.44B | $13.12B | $885.00M | $4.05B | $73.00M | 33.84% | 6.75% | 55.44× | Reported |
| 2023-09-30 | $4.30B | $13.10B | $876.60M | $4.22B | $72.10M | 32.87% | 6.69% | 58.54× | Reported |
| 2023-06-30 | $4.14B | $12.67B | $839.00M | $4.33B | $69.60M | 32.68% | 6.62% | 62.27× | Reported |
| 2023-03-31 | $3.85B | $12.37B | $796.80M | $4.43B | $63.80M | 31.12% | 6.44% | 69.39× | Reported |
| 2022-12-31 | $3.59B | $12.17B | $725.00M | $4.74B | $59.40M | 29.51% | 5.96% | 79.78× | Reported |
| 2022-09-30 | $3.33B | $13.71B | $681.40M | $6.23B | $56.10M | 24.32% | 4.97% | 111.08× | Reported |
| 2022-06-30 | $3.09B | $14.23B | $652.00M | $6.86B | $55.00M | 21.71% | 4.58% | 124.64× | Reported |
| 2022-03-31 | $3.01B | $16.51B | $637.70M | $9.09B | $56.30M | 18.23% | 3.86% | 161.50× | Reported |
| 2021-12-31 | $2.91B | $16.07B | $601.70M | $8.95B | $57.30M | 18.09% | 3.74% | 156.14× | Reported |
| 2021-09-30 | $2.87B | $13.54B | $534.80M | $7.47B | $58.00M | 21.17% | 3.95% | 128.86× | Reported |
| 2021-06-30 | $2.89B | $12.38B | $499.10M | $6.68B | $70.10M | 23.31% | 4.03% | 95.29× | Reported |
| 2021-03-31 | $2.89B | $9.20B | $457.10M | $3.99B | $65.40M | 31.46% | 4.97% | 61.00× | Reported |
| 2020-12-31 | $2.73B | $8.50B | $432.00M | $3.58B | $56.90M | 32.19% | 5.08% | 62.86× | Reported |
| 2020-09-30 | $3.13B | $9.24B | $444.00M | $3.09B | $48.80M | 33.86% | 4.80% | 63.22× | Reported |
| 2020-06-30 | $2.97B | $8.69B | $459.90M | $2.77B | $30.30M | 34.17% | 5.29% | 91.44× | Reported |
| 2020-03-31 | $3.13B | $8.32B | $462.20M | $2.43B | $28.60M | 37.68% | 5.56% | 84.96× | Reported |
| 2019-12-31 | $3.04B | $7.86B | $464.30M | $2.21B | $30.20M | 38.62% | 5.90% | 73.17× | Reported |
| 2019-09-30 | $2.95B | $7.62B | $457.50M | $2.25B | $30.90M | 38.77% | 6.00% | 72.89× | Reported |
| 2019-06-30 | $2.85B | $7.24B | $451.90M | $2.14B | $30.60M | 39.36% | 6.24% | 69.95× | Reported |
| 2019-03-31 | $2.33B | $6.91B | $452.90M | $2.45B | $29.50M | 33.70% | 6.55% | 82.96× | Reported |
| 2018-12-31 | $2.19B | $6.71B | $427.40M | $2.53B | $28.20M | 32.58% | 6.37% | 89.87× | Reported |
| 2018-09-30 | $2.11B | $6.37B | $427.79M | $2.36B | (m) | 33.19% | 6.72% | (m) | (m) |
| 2018-06-30 | $2.09B | $6.20B | $441.45M | $2.29B | (m) | 33.62% | 7.12% | (m) | (m) |
| 2018-03-31 | $2.07B | $6.06B | $455.91M | $2.22B | (m) | 34.07% | 7.52% | (m) | (m) |
| 2017-12-31 | $2.08B | $5.87B | $507.28M | $2.08B | (m) | 35.34% | 8.64% | (m) | (m) |
| 2017-09-30 | $2.03B | $5.52B | $534.70M | $1.89B | (m) | 36.73% | 9.69% | (m) | (m) |
| 2017-06-30 | $2.04B | $5.24B | $540.98M | $1.69B | (m) | 38.95% | 10.33% | (m) | (m) |
| 2017-03-31 | $2.09B | $4.98B | $551.42M | $1.43B | (m) | 41.97% | 11.08% | (m) | (m) |
| 2016-12-31 | $2.05B | $4.86B | $559.88M | $1.33B | (m) | 42.22% | 11.52% | (m) | (m) |
| 2016-09-30 | $2.03B | $4.73B | $563.71M | $1.21B | (m) | 42.99% | 11.91% | (m) | (m) |
| 2016-06-30 | $1.92B | $4.65B | $534.97M | $1.24B | (m) | 41.24% | 11.51% | (m) | (m) |
| 2016-03-31 | $1.75B | $4.43B | $497.54M | $1.30B | (m) | 39.40% | 11.22% | (m) | (m) |
| 2015-12-31 | $1.62B | $4.10B | $459.05M | $1.25B | $14.24M | 39.49% | 11.19% | 87.91× | Reported |
| 2015-09-30 | $1.51B | $3.81B | $399.16M | $1.24B | $16.98M | 39.68% | 10.48% | 72.82× | Reported |
| 2015-06-30 | $1.42B | $3.40B | $364.64M | $1.03B | $24.50M | 41.90% | 10.74% | 42.15× | Reported |
| 2015-03-31 | $1.33B | $3.06B | $335.21M | $915.91M | $31.93M | 43.32% | 10.94% | 28.69× | Reported |
| 2014-12-31 | $1.27B | $2.82B | $307.24M | $838.43M | $37.37M | 45.09% | 10.90% | 22.43× | Reported |
| 2014-09-30 | $1.19B | $2.63B | $280.97M | $803.14M | $42.68M | 45.20% | 10.69% | 18.82× | Reported |
| 2014-06-30 | $1.07B | $2.50B | $252.85M | $857.22M | $45.19M | 42.98% | 10.12% | 18.97× | Reported |
| 2014-03-31 | $967.03M | $2.29B | $226.78M | $792.92M | $46.38M | 42.21% | 9.90% | 17.10× | Reported |
| 2013-12-31 | $859.95M | $2.10B | $198.40M | $760.03M | $46.44M | 40.86% | 9.43% | 16.37× | Reported |
| 2013-09-30 | $772.83M | $1.91B | $173.99M | $693.63M | $46.27M | 40.48% | 9.11% | 14.99× | Reported |
| 2013-06-30 | $707.08M | $1.74B | $148.78M | $659.19M | $45.95M | 40.65% | 8.55% | 14.35× | Reported |
| 2013-03-31 | $666.99M | $1.59B | $123.94M | $588.56M | $45.82M | 42.05% | 7.81% | 12.85× | Reported |
| 2012-12-31 | $625.55M | $1.38B | $94.16M | $457.71M | $45.30M | 45.38% | 6.83% | 10.10× | Reported |
| 2012-09-30 | $573.57M | $1.09B | $78.92M | $266.64M | $43.26M | 52.77% | 7.26% | 6.16× | Reported |
| 2012-06-30 | $543.20M | $762.00M | $71.75M | $5.82M | $35.91M | 71.29% | 9.42% | 0.16× | Reported |
| 2012-03-31 | $538.98M | $565.41M | $64.54M | $-141.98M | $28.72M | 95.32% | 11.41% | -4.94× | Reported |
| 2011-12-31 | $529.51M | $445.82M | $56.09M | $-205.16M | $21.28M | 118.77% | 12.58% | -9.64× | Reported |
| 2011-09-30 | $525.68M | $456.52M | (m) | $-172.53M | $14.29M | 115.15% | (m) | -12.08× | Reported |
| 2011-06-30 | $519.80M | $459.67M | (m) | $-146.17M | $12.46M | 113.08% | (m) | -11.73× | Reported |
| 2011-03-31 | $501.17M | $467.74M | (m) | $-109.58M | $10.75M | 107.15% | (m) | -10.19× | Reported |
| 2010-12-31 | $489.25M | $459.07M | (m) | $-97.47M | $9.12M | 106.57% | (m) | -10.69× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $398.76M | $379.27M | (m) | $-74.10M | $2.34M | 105.14% | (m) | -31.71× | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $274.90M | $238.46M | (m) | $-86.25M | $7.75M | 115.28% | (m) | -11.13× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |